Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Kasus penyakit LES mempunyai prevalensi yang cukup tinggi di Indonesia dan dunia. Prevalensi di berbagai negara sangat bervariasi antara 2.9/100.000 – 400/100.000. Namun, belum terdapat data epidemiologi LES yang mencakup semua wilayah Indonesia. Diagnosis Lupus Eritematosus Sistemik tidak mudah dan sering terlambat akibat dari gejala yang timbul menyerupai gejala berbagai penyakit sehingga Lupus dikenal dengan sebutan penyakit 1000 wajah. Gejala penyakit Lupus sangat beragam, mulai dari gejala ringan hingga yang dapat mengakibatkan kematian. Penelitian berupa kajian kepustakaan (literature review) terhadap 3 jurnal penelitian internasional pada tahun 2000-2020. Penelitian ini bertujuan untuk mengetahui peran faktor risiko paparan silika pada kejadian Lupus Eritematosus Sistemik. Hasil penelitian menunjukan bahwa terdapat hubungan yang signifikan antara paparan silika dengan kejadian Lupus Eritematosus Sistemik dengan rata-rata OR 3,6. Paparan silika yang terhirup tidak mungkin menjadi penyebab utama LES pada populasi umum, namun paparan silika menjadi salah satu faktor risiko yang berperan dalam pengembangan penyakit LES. Memahami mekanisme yang digunakan oleh silika dalam LES dapat membantu kita lebih memahami peran paparan lingkungan terutama paparan silika pada LES. ......Literature Review: The Role of Risk Factors for Silica Exposure in Systemic Lupus Erythematosus. Systematic Lupus Erythematosus have a high prevalence in Indonesia and the world. Prevalence in various countries varies greatly between 2.9 / 100.000 - 400/100,000. However, there are no epidemiological data covering all regions of Indonesia for SLE. Diagnoses of Systemic Lupus Erythematosus is not easy and often late due to symptoms that resemble the symptoms of various diseases, so that Lupus is known as 1000 facial diseases. Symptoms of lupus are very diverse, ranging from mild symptoms to those that can result in death. The research was in the form of a literature review of 8 international research journals in 2000-2020. This study aims to determine the role of risk factors for silica exposure in the incidence of Systemic Lupus Erythematosus. The results showed that there was a significant relationship between exposure to silica with the incidence of Systemic Lupus Erythematosus with an average OR of 3.6. Exposure to inhaled silica may not be a major cause of SLE in the general population, but silica exposure is one of the risk factors that play a role in the development of LES disease. Understanding the mechanism used by silica in SLE can help us better understand the role of environmental exposure especially silica exposure in SLE.

Abstrak :
Penelitian ini membahas tentang bagaimana bentuk stres yang dirasakan oleh Orang dengan Penyakit Lupus akibat keberadaan diagnosa dan kondisi fisik mereka yang mengidap penyakit lupus. Orang dengan Penyakit Lupus menggunakan dukungan sosial yang diperoleh dari anggota keluarga terdekat mereka dalam mengelola dan mengurangi stres yang mereka rasakan. Penelitian ini dilakukan melalui pendekatan kualitatif dengan metode studi kasus. Hasil penelitian ini menggambarkan bahwa bentuk dukungan emosional, instrumental, informasi, dan jaringan sosial yang diperoleh dari anggota keluarga terdekat dapat membantu Orang dengan Penyakit Lupus mengelola dan mengurangi bentuk stres fisiologis, psikologis, dan tingkah laku yang mereka rasakan. ......This research describes the forms of stress experienced by people diagnosed lupus as well as the impact of their illness to their physical condition. People with lupus used social support from close family in coping and reducing stress. The approach used qualitative with case study method. Study concludes that emotional, instrumental, information, and social network supports from close family member can be positive in coping and reducing physiological, psychological, and behavioral stress in people with lupus.

Abstrak :
Lupus eritematosus sistemik merupakan penyakit autoimun sistemik yang menghasilkan berbagai autoantibodi yang ditujukan terhadap komponen sel, seperti inti sel, sitoplasma dan membran sel. Salah satu autoantibodi tersebut yaitu antibodi anti ?2GP-1 dihubungkan dengan kejadian aterosklerosis dan penyakit kardiovaskular yang timbul lebih dini pada pasien SLE. Penelitian ini bertujuan untuk mengetahui hubungan antibodi anti ?2GP-1 dengan disfungsi endotel dan aterosklerosis pada pasien SLE dan disfungsi endotel pada HUVEC. Penelitian potong lintang pada pasien SLE yang memenuhi kriteria inklusi menurut ACR 1997 di poliklinik khusus Reumatologi, Alergi Imunologi RSCM dan poliklinik khusus Reumatologi RSUP Dr. M. Djamil dari Maret 2016 sampai dengan Juli 2017. Subjek secara acak dibagi atas 2 kelompok berdasarkan nilai CIMT. Dilakukan pemeriksaan antibodi anti ?2GP-1, ox-LDL, ADMA, ICAM-1, VCAM-1, ET-1. Dilakukan pemajanan antibodi anti ?2GP-1 yang berasal dari kelompok aterosklerosis positif dan kontrol pada HUVEC. Enam puluh enam orang subjek direkrut pada penelitian ini, terdiri atas 33 orang aterosklerosis positif dan 33 orang aterosklerosis negatif dan 6 orang kontrol dengan rentang umur 20-45 tahun. Ditemukan korelasi positif antara antibodi anti ?2GP-1 dengan CIMT,ADMA, ICAM-1, VCAM-1 dan ET-1 dengan nilai r = 0,409, 0,89, 0,36, 0,43, 0,37 dan dengan p < 0,05. Tidak ditemukan korelasi antibodi anti ?2GP-1 dengan ox-LDL dengan r = 0,025 dan p > 0,05. Ditemukan perbedaan bermakna kadar antibodi anti ?2GP-1, ADMA, ICAM-1, VCAM-1 dan ET-1 pada kelompok aterosklerosis positif dengan kelompok aterosklerosis negatif dengan nilai p < 0,05, sedangkan kadar ox-LDL tidak ada perbedaan bermakna pada kedua kelompok tersebut dengan nilai p > 0,05. Hasil pemajanan antibodi anti ?2GP-1 pada HUVEC mendapatkan perbedaan bermakna peningkatan kadar ICAM-1, VCAM-1 dan ET-1 pada kelompok SLE aterosklerosis positif dari kontrol dengan nilai p < 0,05. Antibodi anti ?2GP-1 menimbulkan disfungsi endotel pada pasien SLE. ...... Systemic lupus erythematosus SLE is a multi systemic disease characterized by a wide variety of autoantibodies directed to several self molecules found in the nucleus, cytoplasm and cell membrane. One of variety autoantibodies is Antibody anti 2GP 1 which associated with atherosclerosis and premature cardiovascular disease in SLE patients. The purpose of the study is to know the association of antibody anti 2GP 1 with endothelial dysfunction and atherosclerosis in SLE and endothelial dysfunction in HUVEC. Cross sectional study was performed in SLE patients fulfill inclussion criteria according ACR 1997 out patients in Rheumatology and Alergy Immunology polyclinic of Cipto Mangunkusomo Hospital and Dr. M. Djamil Hospital from March 2016 to July 2017. Patients were divided in 2 groups based on CIMT. Examination of antibody anti 2GP 1, ox LDL, ADMA, ICAM 1, VCAM 1 and ET 1 were performed. Purified antibody anti 2GP 1 from positive atherosclerosis and controls groups were exposed to HUVEC. Sixty six patients were enrolled, consists of 33 patients with positive atherosclerosis, 33 patients with negative atherosclerosis and 6 as healthy control with range of age 20 40 year. In this study we found positive correlation between antibody anti 2GP 1 with CIMT, ADMA, ICAM 1, VCAM 1 and ET 1 with r 0.409, 0.89, 0.36, 0.43, 0.43 respectively and p value 0.05. There was no correlation between antibody anti 2GP 1 with ox LDL, r 0.025 and p 0.05. There were significantly different levels of antibody anti 2GP 1, ADMA, ICAM 1, VCAM 1 and ET 1 in positive atherosclerosis compared to negative atherosclerosis group with p 0.05. Level of ox LDL was not different between the two groups with p 0.05. There were significantly different increase of ICAM 1, VCAM 1 and ET 1 levels in HUVEC which was exposed with purified antibody anti 2GP 1 from positive atherosclerosis compared to control with p 0.05. Antibody anti 2GP 1 cause endothelial dysfunction in SLE patients.

Abstrak :
Often considered the prototypic autoimmune disease, Lupus is characterized by protean manifestations and affects a wide range of organ systems. Despite widespread availability of anti nuclear antibody testing and other technological diagnostic advances, the diagnosis of lupus can be elusive, difficult, and inexact. Treatment of the disease can also be challenging. Advances in immunology and biotechnology have led to a burgeoning world of new therapies in development that offer patients the real possibility of new therapies and physicians and scientists novel insights into the pathogenesis of this complicated immunological disease. Lupus erythematosus : clinical evaluation and treatment summarizes the clinical aspects of lupus facing the general clinician in the 21st century. In this invaluable, practical book, the reader will find introductory chapters regarding general diagnostic and treatment principles, followed by chapters addressing the lupus-specific organ manifestations. Special topics regarding pregnancy and comorbidities are also presented. Written by highly experienced physicians with special expertise in lupus.